<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Res Methodol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med Res Methodol</journal-id><journal-title-group><journal-title>BMC Medical Research Methodology</journal-title></journal-title-group><issn pub-type="epub">1471-2288</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25524326</article-id><article-id pub-id-type="pmc">4277823</article-id><article-id pub-id-type="publisher-id">1137</article-id><article-id pub-id-type="doi">10.1186/1471-2288-14-134</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tang</surname><given-names>Nian-Sheng</given-names></name><address><email>nstang@ynu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Bin</given-names></name><address><email>yubin-666@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Man-Lai</given-names></name><address><email>mltang@hsmc.edu.hk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Statistics, Yunnan University, No.2 Cuihu North Road, 650091 Kunming, China </aff><aff id="Aff2"><label/>Department of Mathematics and Statistics, Hang Seng Management College, Hang Seng Link, Siu Lek Yuen, Shatin NT, Hong Kong, China </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>134</elocation-id><history><date date-type="received"><day>4</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Tang et al.; licensee BioMed Central. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>A two-arm non-inferiority trial without a placebo is usually adopted to demonstrate that an experimental treatment is not worse than a reference treatment by a small pre-specified <italic>non-inferiority margin</italic> due to ethical concerns. <italic>Selection of the non-inferiority margin</italic> and <italic>establishment of assay sensitivity</italic> are two major issues in the design, analysis and interpretation for two-arm non-inferiority trials. Alternatively, a three-arm non-inferiority clinical trial including a placebo is usually conducted to assess the assay sensitivity and internal validity of a trial. Recently, some large-sample approaches have been developed to assess the non-inferiority of a new treatment based on the three-arm trial design. However, these methods behave badly with small sample sizes in the three arms. This manuscript aims to develop some reliable small-sample methods to test three-arm non-inferiority.</p></sec><sec><title>Methods</title><p>Saddlepoint approximation, exact and approximate unconditional, and bootstrap-resampling methods are developed to calculate p-values of the Wald-type, score and likelihood ratio tests. Simulation studies are conducted to evaluate their performance in terms of type I error rate and power.</p></sec><sec><title>Results</title><p>Our empirical results show that the saddlepoint approximation method generally behaves better than the asymptotic method based on the Wald-type test statistic. For small sample sizes, approximate unconditional and bootstrap-resampling methods based on the score test statistic perform better in the sense that their corresponding type I error rates are generally closer to the prespecified nominal level than those of other test procedures.</p></sec><sec><title>Conclusions</title><p>Both approximate unconditional and bootstrap-resampling test procedures based on the score test statistic are generally recommended for three-arm non-inferiority trials with binary outcomes.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Approximate unconditional test</kwd><kwd>Bootstrap-resampling test</kwd><kwd>Non-inferiority trial</kwd><kwd>Rate difference</kwd><kwd>Saddlepoint approximation</kwd><kwd>Three-arm design</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>The objective of a non-inferiority trial is to demonstrate the efficacy of an experimental treatment not being inferior to a reference treatment by some pre-specified non-inferiority margin. Many authors considered two-arm non-inferiority trials without a placebo since the comparison between the experimental and reference treatments is direct and the potential ethical problems encountered in traditional placebo-controlled trials are avoided (for example, see Dunnett and Gent [<xref ref-type="bibr" rid="CR1">1</xref>], Tango [<xref ref-type="bibr" rid="CR2">2</xref>], and Tang et al. [<xref ref-type="bibr" rid="CR3">3</xref>]). However, there are two major concerns for two-arm non-inferiority trials [<xref ref-type="bibr" rid="CR4">4</xref>]. The first issue is the choice of the non-inferiority margin, which is the clinically acceptable amount or a combination of statistical reasoning and clinical judgement. The other issue is the evaluation of assay sensitivity, which refers to the ability of a trial to differentiate an effective treatment from a less effective or ineffective treatment [<xref ref-type="bibr" rid="CR5">5</xref>]. Without a placebo arm, the assay sensitivity of a trail is not demonstrable from the trial data and ones must rely on some external information (e.g., historical placebo trails) for the reference treatment [<xref ref-type="bibr" rid="CR4">4</xref>]. Without the trial assay sensitivity, any non-inferiority testing results from the comparison of the experimental and reference treatments will become unconvincing. There are some indications where it is considered ethically acceptable to continue to randomize patients to placebo despite the fact that an effective treatment exists and there is interest in seeing not only whether the new treatment works at all but also how it measures up to accepted therapy. In this case, a three-arm non-inferiority clinical trail including the experimental treatment, an active reference treatment and a placebo is usually conducted to assess assay sensitivity and internal validation of a trail [<xref ref-type="bibr" rid="CR6">6</xref>]. Indeed, three-arm trials are recommended in the guidelines of the ICH (The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) and EMEA/CPMP (European Medicines Agency/Committee for Proprietary Medical Products) as a useful approach to the assessment of assay sensitivity and internal validation (e.g., see [<xref ref-type="bibr" rid="CR7">7</xref>]).</p><p>Statistical inference based on three-arm non-inferiority clinical trials with normally distributed outcomes has received considerable attention in recent years. For example, Koch and Tangen [<xref ref-type="bibr" rid="CR8">8</xref>] and Pigeot et al. [<xref ref-type="bibr" rid="CR9">9</xref>] considered the problem of three-arm non-inferiority testing for normally distributed endpoints with a common but unknown variance. Koti [<xref ref-type="bibr" rid="CR10">10</xref>] presented a new approach for normally distributed endpoints based on the Fieller-Hinkley distribution. Hasler, Vonk and Hothorn [<xref ref-type="bibr" rid="CR11">11</xref>] proposed the usage of the <italic>t</italic>-distribution in the presence of heteroscedasticity. Hida and Tango [<xref ref-type="bibr" rid="CR7">7</xref>] proposed a test procedure for assessing the assay sensitivity with a pre-specified margin defined as a difference between treatments in the presence of homoscedasticity. Ghosh, Nathoo, G&#x000f6;nen and Tiwari [<xref ref-type="bibr" rid="CR12">12</xref>] developed a Bayesian approach in the presence of heteroscedasticity by incorporating both parametric and semi-parametric models. Gamalo, Muthukumarana, Ghosh and Tiwari [<xref ref-type="bibr" rid="CR13">13</xref>] extended the existing generalized p-value approach for assessing the non-inferiority of a new treatment in a three-arm trial.</p><p>Recently, some statistical methods have also been developed for three-arm non-inferiority testing with binary endpoints. For example, Tang and Tang [<xref ref-type="bibr" rid="CR14">14</xref>] proposed two asymptotic approaches for testing three-arm non-inferiority via rate difference based on Wald-type and score test statistics. Kieser and Friede (2007) revisited the performance of Tang and Tang&#x02019;s [<xref ref-type="bibr" rid="CR14">14</xref>] asymptotic test statistics via simulation studies and derived approximate sample size formulae for achieving the desired power. Munk, Mielke, Skipka and Freitag [<xref ref-type="bibr" rid="CR15">15</xref>] developed likelihood ratio tests. Li and Gao [<xref ref-type="bibr" rid="CR4">4</xref>] used the closed testing principle to establish the hierarchical testing procedure and proposed a group sequential type design. Liu, Tzeng and Tsou [<xref ref-type="bibr" rid="CR16">16</xref>] presented a three-step testing procedure and derived an optimal sample size allocation rule in an ethical and reliable manner that minimizes the total sample size.</p><p>All aforementioned approaches for testing non-inferiority of a new treatment in a three-arm clinical trial with binary endpoints are based on large sample theory, and their accuracy has long been suspected and criticized when sample sizes are small or the data structure is sparse. To the best of our knowledge, limited work have been done to address these issues. Motivated by Jensen [<xref ref-type="bibr" rid="CR17">17</xref>], we derive saddlepoint approximations to the cumulative distribution functions of Wald-type, score and likelihood ratio test statistics. Inspired by Tang and Tang [<xref ref-type="bibr" rid="CR18">18</xref>], we also propose the exact unconditional, approximate unconditional and Bootstrap-resampling <italic>p</italic>-value calculation procedures for testing three-arm non-inferiority with small sample sizes.</p><p>The rest of this article is organized as follows. We first review three test statistics for assessing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints. We also propose saddlepoint approximation, exact and approximate unconditional, and bootstrap-resampling approaches for calculating <italic>p</italic>-values. Simulation studies are conducted to investigate the performance of all test statistics based on different <italic>p</italic>-value calculation approaches in terms of type I error rate and power. An example is analyzed to demonstrate our methodologies. Finally, we discuss the performance of our proposed methodologies and present some conclusions.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Model</title><p>Let consider a clinical trial with the test (T), reference (R) and placebo (P) treatments, and assume their primary clinical outcomes <italic>X</italic><sub><italic>T</italic></sub>, <italic>X</italic><sub><italic>R</italic></sub> and <italic>X</italic><sub><italic>P</italic></sub> be independent and binomially distributed as <italic>X</italic><sub><italic>T</italic></sub>&#x0223c;Bin(<italic>n</italic><sub><italic>T</italic></sub>,<italic>&#x003c0;</italic><sub><italic>T</italic></sub>), <italic>X</italic><sub><italic>R</italic></sub>&#x0223c;Bin(<italic>n</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>) and <italic>X</italic><sub><italic>P</italic></sub>&#x0223c;Bin(<italic>n</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>P</italic></sub>), respectively. Here, <italic>X</italic><sub><italic>T</italic></sub>,<italic>X</italic><sub><italic>R</italic></sub> and <italic>X</italic><sub><italic>P</italic></sub> are the numbers of responses in groups T, R and P, respectively, <italic>&#x003c0;</italic><sub><italic>T</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub> represent their corresponding response probabilities with higher probability indicating a more favorable outcome, and <italic>n</italic><sub><italic>T</italic></sub>,<italic>n</italic><sub><italic>R</italic></sub> and <italic>n</italic><sub><italic>P</italic></sub> denote their corresponding sample sizes. Thus, the joint probability density function of (<italic>x</italic><sub><italic>T</italic></sub>,<italic>x</italic><sub><italic>R</italic></sub>,<italic>x</italic><sub><italic>P</italic></sub>) is given by
<disp-formula id="Equ1"><label>2.1</label><graphic xlink:href="12874_2014_1137_Equ1_HTML.gif" position="anchor"/></disp-formula></p><p>It can be easily shown from Equation (<xref rid="Equ2" ref-type="">2</xref>.1) that the maximum likelihood estimates (MLEs) of <italic>&#x003c0;</italic><sub><italic>T</italic></sub>, <italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub> are given by <inline-formula id="IEq1"><inline-graphic xlink:href="12874_2014_1137_IEq1_HTML.gif"/></inline-formula>, <inline-formula id="IEq2"><inline-graphic xlink:href="12874_2014_1137_IEq2_HTML.gif"/></inline-formula> and <inline-formula id="IEq3"><inline-graphic xlink:href="12874_2014_1137_IEq3_HTML.gif"/></inline-formula>, respectively.</p></sec><sec id="Sec4"><title>Test statistics</title><p>Following Hida and Tango [<xref ref-type="bibr" rid="CR7">7</xref>], to test the non-inferiority of the experimental treatment to the reference with the assay sensitivity in a three-arm trial, we have to simultaneously demonstrate (i) the superiority of the experimental treatment to the placebo, (ii) the non-inferiority of the experimental treatment to the reference with a non-inferiority margin <italic>&#x00394;</italic>&#x0003e;0, and (iii) the superiority of the reference treatment to the placebo by more than <italic>&#x00394;</italic>. That is, <italic>&#x003c0;</italic><sub><italic>T</italic></sub>, <italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub> must satisfy the following inequalities: <italic>&#x003c0;</italic><sub><italic>P</italic></sub>&#x0003c;<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02212;<italic>&#x00394;</italic>&#x0003c;<italic>&#x003c0;</italic><sub><italic>T</italic></sub>, which can be written as the following two hypotheses:
<disp-formula id="Equa"><graphic xlink:href="12874_2014_1137_Equa_HTML.gif" position="anchor"/></disp-formula><disp-formula id="Equb"><graphic xlink:href="12874_2014_1137_Equb_HTML.gif" position="anchor"/></disp-formula></p><p>Similar to Pigeot et al. [<xref ref-type="bibr" rid="CR9">9</xref>], we take the margin <italic>&#x00394;</italic> as a fraction <italic>f</italic> of the effect size of the reference treatment, i.e., <italic>&#x00394;</italic>=<italic>f</italic>(<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02212;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>). Generally, one can select <italic>f</italic>=1/2 and 1/3 [<xref ref-type="bibr" rid="CR14">14</xref>]. Thus, the second hypothesis can be expressed as <italic>K</italic><sub>0</sub>:<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02264;<italic>&#x003c0;</italic><sub><italic>P</italic></sub> versus <italic>K</italic><sub>1</sub>:<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x0003e;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>. If <italic>K</italic><sub>0</sub> is rejected, letting <italic>f</italic>=1&#x02212;<italic>&#x003b8;</italic> yields the following non-inferiority hypothesis:
<disp-formula id="Equ2"><label>2.2</label><graphic xlink:href="12874_2014_1137_Equ2_HTML.gif" position="anchor"/></disp-formula></p><p>where <italic>&#x003b8;</italic>&#x02208;(0,1) is a fixed retention fraction [<xref ref-type="bibr" rid="CR8">8</xref>]. Rejecting <italic>H</italic><sub>0</sub> implies that the test treatment preserves at least 100<italic>&#x003b8;</italic><italic>%</italic> of the efficacy of the reference treatment compared to placebo [<xref ref-type="bibr" rid="CR19">19</xref>]. Similar to Tang and Tang [<xref ref-type="bibr" rid="CR14">14</xref>], we only consider hypothesis <italic>H</italic><sub>0</sub> and assume that <italic>K</italic><sub>0</sub> is rejected at some pre-given significant level. Thus, the non-inferiority hypothesis (2.2) can be rewritten as
<disp-formula id="Equ3"><label>2.3</label><graphic xlink:href="12874_2014_1137_Equ3_HTML.gif" position="anchor"/></disp-formula></p><p>Let <italic>&#x003c8;</italic>=<italic>&#x003c0;</italic><sub><italic>T</italic></sub>&#x02212;<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02212;(1&#x02212;<italic>&#x003b8;</italic>)<italic>&#x003c0;</italic><sub><italic>P</italic></sub>. The non-inferiority hypothesis (2.3) can be expressed as
<disp-formula id="Equ4"><label>2.4</label><graphic xlink:href="12874_2014_1137_Equ4_HTML.gif" position="anchor"/></disp-formula></p><p>The restricted maximum likelihood estimates (RMLEs) (denoted by <inline-formula id="IEq4"><inline-graphic xlink:href="12874_2014_1137_IEq4_HTML.gif"/></inline-formula>) of <italic>&#x003c0;</italic><sub><italic>T</italic></sub>, <italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub> can be computed as follows. If the MLEs <inline-formula id="IEq5"><inline-graphic xlink:href="12874_2014_1137_IEq5_HTML.gif"/></inline-formula> of <italic>&#x003c0;</italic><sub><italic>T</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>P</italic></sub> satisfy the conditions: <inline-formula id="IEq6"><inline-graphic xlink:href="12874_2014_1137_IEq6_HTML.gif"/></inline-formula> and <inline-formula id="IEq7"><inline-graphic xlink:href="12874_2014_1137_IEq7_HTML.gif"/></inline-formula>, we take <inline-formula id="IEq8"><inline-graphic xlink:href="12874_2014_1137_IEq8_HTML.gif"/></inline-formula>, <inline-formula id="IEq9"><inline-graphic xlink:href="12874_2014_1137_IEq9_HTML.gif"/></inline-formula> and <inline-formula id="IEq10"><inline-graphic xlink:href="12874_2014_1137_IEq10_HTML.gif"/></inline-formula>; otherwise, the RMLEs can be calculated by setting <italic>&#x003c0;</italic><sub><italic>T</italic></sub>=<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>+(1&#x02212;<italic>&#x003b8;</italic>)<italic>&#x003c0;</italic><sub><italic>P</italic></sub> in the likelihood function (2.1) and maximizing it with respect to <italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub>. For the latter, it follows from Equation (<xref rid="Equ2" ref-type="">2</xref>.1) that the RMLEs of <italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub> can be obtained by simultaneously solving the following equations in the parameter space <italic>&#x00398;</italic>={(<italic>&#x003c0;</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>):0&#x02264;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>&#x0003c;<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02264;1}:
<disp-formula id="Equc"><graphic xlink:href="12874_2014_1137_Equc_HTML.gif" position="anchor"/></disp-formula></p><p>It is possible that there is no point (<italic>&#x003c0;</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>) &#x02208;<italic>&#x00398;</italic> such that it satisfies the above equations, which implies that the likelihood function given in Equation (<xref rid="Equ2" ref-type="">2</xref>.1) attains its maximum on the boundary of the parameter space <italic>&#x00398;</italic>.</p><p>Following Tang and Tang [<xref ref-type="bibr" rid="CR14">14</xref>], <italic>&#x003c8;</italic> can be estimated by <inline-formula id="IEq11"><inline-graphic xlink:href="12874_2014_1137_IEq11_HTML.gif"/></inline-formula>, and its variance is given by <inline-formula id="IEq12"><inline-graphic xlink:href="12874_2014_1137_IEq12_HTML.gif"/></inline-formula>, which can be estimated by <inline-formula id="IEq13"><inline-graphic xlink:href="12874_2014_1137_IEq13_HTML.gif"/></inline-formula>, where <inline-formula id="IEq14"><inline-graphic xlink:href="12874_2014_1137_IEq14_HTML.gif"/></inline-formula> is some appropriate estimate of <italic>&#x003c0;</italic>=(<italic>&#x003c0;</italic><sub><italic>T</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>P</italic></sub>), for example, taking <inline-formula id="IEq15"><inline-graphic xlink:href="12874_2014_1137_IEq15_HTML.gif"/></inline-formula> to be <inline-formula id="IEq16"><inline-graphic xlink:href="12874_2014_1137_IEq16_HTML.gif"/></inline-formula> or <inline-formula id="IEq17"><inline-graphic xlink:href="12874_2014_1137_IEq17_HTML.gif"/></inline-formula> which is the RMLE of <italic>&#x003c0;</italic>. Thus, the statistics for testing hypothesis (2.4) are given by
<disp-formula id="Equd"><graphic xlink:href="12874_2014_1137_Equd_HTML.gif" position="anchor"/></disp-formula></p><p>which are asymptotically distributed as the standard normal distribution under <italic>H</italic><sub>0</sub> as <italic>n</italic><sub><italic>T</italic></sub>, <italic>n</italic><sub><italic>R</italic></sub> and <italic>n</italic><sub><italic>P</italic></sub> are sufficiently large. Hence, non-inferiority can be claimed if <italic>T</italic><sub><italic>W</italic></sub>&#x0003e;<italic>z</italic><sub>1&#x02212;<italic>&#x003b1;</italic></sub> (or <italic>T</italic><sub><italic>R</italic></sub>&#x0003e;<italic>z</italic><sub>1&#x02212;<italic>&#x003b1;</italic></sub>), where <italic>z</italic><sub>1&#x02212;<italic>&#x003b1;</italic></sub> is the (1&#x02212;<italic>&#x003b1;</italic>)-quantile of the standard normal distribution. When <italic>&#x003c0;</italic><sub><italic>P</italic></sub>=0, <italic>T</italic><sub><italic>W</italic></sub> is the Wald-type statistic proposed in Blackwelder [<xref ref-type="bibr" rid="CR20">20</xref>] and <italic>T</italic><sub><italic>R</italic></sub> is the test statistic given by Farrington and Manning [<xref ref-type="bibr" rid="CR21">21</xref>] for two-arm noninferiority trials.</p><p>The signed root of the likelihood ratio statistic for testing hypothesis (2.4) is given by
<disp-formula id="Eque"><graphic xlink:href="12874_2014_1137_Eque_HTML.gif" position="anchor"/></disp-formula></p><p>which is asymptotically distributed as the standard normal distribution under <italic>H</italic><sub>0</sub> as <italic>n</italic><sub><italic>T</italic></sub>, <italic>n</italic><sub><italic>R</italic></sub> and <italic>n</italic><sub><italic>P</italic></sub> are sufficiently large, where <inline-formula id="IEq18"><inline-graphic xlink:href="12874_2014_1137_IEq18_HTML.gif"/></inline-formula> with <inline-formula id="IEq19"><inline-graphic xlink:href="12874_2014_1137_IEq19_HTML.gif"/></inline-formula>. Thus, non-inferiority can be claimed if <italic>T</italic><sub><italic>L</italic></sub>&#x0003e;<italic>z</italic><sub>1&#x02212;<italic>&#x003b1;</italic></sub>.</p></sec><sec id="Sec5"><title><italic>p</italic>-value calculation methods</title><p>The non-inferiority hypothesis (2.2) can be claimed via the <italic>p</italic>-value method with the rule: <italic>H</italic><sub>0</sub> is rejected if the <italic>p</italic>-value is less than or equal to the prespecified significance level <italic>&#x003b1;</italic>. In what follows, we introduce five approaches for calculating <italic>p</italic>-values based on <inline-formula id="IEq20"><inline-graphic xlink:href="12874_2014_1137_IEq20_HTML.gif"/></inline-formula>, which is the observed value of test statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) for the observed value <inline-formula id="IEq21"><inline-graphic xlink:href="12874_2014_1137_IEq21_HTML.gif"/></inline-formula> of (<italic>X</italic><sub><italic>T</italic></sub>,<italic>X</italic><sub><italic>R</italic></sub>,<italic>X</italic><sub><italic>P</italic></sub>).</p><sec id="Sec6"><title>(1) Asymptotic method (AM)</title><p>It follows from the above arguments that all statistics <italic>T</italic><sub><italic>j</italic></sub>&#x02019;s (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) asymptotically follow the standard normal distribution under the null hypothesis <italic>H</italic><sub>0</sub>:<italic>&#x003c8;</italic>&#x02264;0. Thus, the asymptotic <italic>p</italic>-value for testing hypothesis (2.2) via statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) based on <inline-formula id="IEq22"><inline-graphic xlink:href="12874_2014_1137_IEq22_HTML.gif"/></inline-formula> can be calculated by <inline-formula id="IEq23"><inline-graphic xlink:href="12874_2014_1137_IEq23_HTML.gif"/></inline-formula>, where <italic>&#x003a6;</italic>(&#x000b7;) is the standard normal distribution function.</p><p>The above asymptotic approach for calculating <italic>p</italic>-value of testing hypothesis (2.2) via statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic><italic>W</italic>,<italic>L</italic>) is established under the large sample theory. Its accuracy has long been suspected and criticized, especially when <italic>n</italic><sub><italic>T</italic></sub>, <italic>n</italic><sub><italic>R</italic></sub> and/or <italic>n</italic><sub><italic>P</italic></sub> are small since the skewness of the underlying binomial distributions is not taken into consideration. Some higher order corrections such as the saddlepoint approximation [<xref ref-type="bibr" rid="CR17">17</xref>] have been proposed to improve the accuracy of the normal approximation. In what follows, we will derive saddlepoint approximations to distributions of the three test statistics.</p></sec><sec id="Sec7"><title>(2) Saddlepoint approximation method (SAM)</title><p>Since <italic>X</italic><sub><italic>T</italic></sub>, <italic>X</italic><sub><italic>R</italic></sub> and <italic>X</italic><sub><italic>P</italic></sub> are independent and <italic>X</italic><sub><italic>i</italic></sub>&#x0223c;Bin(<italic>n</italic><sub><italic>i</italic></sub>,<italic>&#x003c0;</italic><sub><italic>i</italic></sub>) (<italic>i</italic>=<italic>T</italic>,<italic>R</italic>,<italic>P</italic>), the moment generating function of <inline-formula id="IEq24"><inline-graphic xlink:href="12874_2014_1137_IEq24_HTML.gif"/></inline-formula> is given by
<disp-formula id="Equf"><graphic xlink:href="12874_2014_1137_Equf_HTML.gif" position="anchor"/></disp-formula></p><p>with the cumulant generating function being
<disp-formula id="Equg"><graphic xlink:href="12874_2014_1137_Equg_HTML.gif" position="anchor"/></disp-formula></p><p>where &#x02212;1&#x02264;<italic>t</italic>&#x02264;1. Thus, the first two derivatives of the cumulant generating function <italic>K</italic>(<italic>t</italic>) are given by
<disp-formula id="Equh"><graphic xlink:href="12874_2014_1137_Equh_HTML.gif" position="anchor"/></disp-formula></p><p>respectively. To obtain the saddlepoint approximation to <inline-formula id="IEq25"><inline-graphic xlink:href="12874_2014_1137_IEq25_HTML.gif"/></inline-formula>, we need to solve the following saddlepoint equation: <inline-formula id="IEq26"><inline-graphic xlink:href="12874_2014_1137_IEq26_HTML.gif"/></inline-formula> whose unique solution is denoted as <inline-formula id="IEq27"><inline-graphic xlink:href="12874_2014_1137_IEq27_HTML.gif"/></inline-formula>. Following Jing and Robinson [<xref ref-type="bibr" rid="CR22">22</xref>], the saddlepoint approximation to the cumulative distribution function of statistic <inline-formula id="IEq28"><inline-graphic xlink:href="12874_2014_1137_IEq28_HTML.gif"/></inline-formula> is given by
<disp-formula id="Equi"><graphic xlink:href="12874_2014_1137_Equi_HTML.gif" position="anchor"/></disp-formula></p><p>where <inline-formula id="IEq29"><inline-graphic xlink:href="12874_2014_1137_IEq29_HTML.gif"/></inline-formula> and <inline-formula id="IEq30"><inline-graphic xlink:href="12874_2014_1137_IEq30_HTML.gif"/></inline-formula>. Thus, the saddlepoint approximation to <inline-formula id="IEq31"><inline-graphic xlink:href="12874_2014_1137_IEq31_HTML.gif"/></inline-formula> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) is given by
<disp-formula id="Equj"><graphic xlink:href="12874_2014_1137_Equj_HTML.gif" position="anchor"/></disp-formula></p><p>where <inline-formula id="IEq32"><inline-graphic xlink:href="12874_2014_1137_IEq32_HTML.gif"/></inline-formula> and <inline-formula id="IEq33"><inline-graphic xlink:href="12874_2014_1137_IEq33_HTML.gif"/></inline-formula>, <inline-formula id="IEq34"><inline-graphic xlink:href="12874_2014_1137_IEq34_HTML.gif"/></inline-formula> is the unique solution to equation: <inline-formula id="IEq35"><inline-graphic xlink:href="12874_2014_1137_IEq35_HTML.gif"/></inline-formula> for <italic>j</italic>=<italic>W</italic>,<italic>R</italic> with <inline-formula id="IEq36"><inline-graphic xlink:href="12874_2014_1137_IEq36_HTML.gif"/></inline-formula> and <inline-formula id="IEq37"><inline-graphic xlink:href="12874_2014_1137_IEq37_HTML.gif"/></inline-formula>, <inline-formula id="IEq38"><inline-graphic xlink:href="12874_2014_1137_IEq38_HTML.gif"/></inline-formula> and <inline-formula id="IEq39"><inline-graphic xlink:href="12874_2014_1137_IEq39_HTML.gif"/></inline-formula> with <inline-formula id="IEq40"><inline-graphic xlink:href="12874_2014_1137_IEq40_HTML.gif"/></inline-formula>, and <inline-formula id="IEq41"><inline-graphic xlink:href="12874_2014_1137_IEq41_HTML.gif"/></inline-formula>.</p></sec><sec id="Sec8"><title>(3) Exact unconditional method (EUM)</title><p>When sample sizes (i.e., <italic>n</italic><sub><italic>T</italic></sub>,<italic>n</italic><sub><italic>R</italic></sub>,<italic>n</italic><sub><italic>P</italic></sub>) are small, asymptotic methods may yield inflated type I error rates and their exact versions may provide reliable alternative. Under <italic>H</italic><sub>0</sub>:<italic>&#x003c8;</italic>&#x02264;0 with <italic>&#x003c0;</italic><sub><italic>P</italic></sub>&#x0003c;<italic>&#x003c0;</italic><sub><italic>R</italic></sub>, parameters <italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub> must belong to the following constrained parameter space <italic>&#x003a9;</italic>={(<italic>&#x003c0;</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>):0&#x02264;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>&#x0003c;<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02264;1 if &#x02212;<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x0003c;<italic>&#x003c8;</italic>&#x0003c;0, (&#x02212;<italic>&#x003c8;</italic>&#x02212;<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>)/(1&#x02212;<italic>&#x003b8;</italic>)&#x02264;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>&#x0003c;<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x0003c;1 if &#x02212;<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x0003c;<italic>&#x003c8;</italic>&#x02264;&#x02212;<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>, and empty set otherwise }. Under the null hypothesis, the probability density function (2.1) can be reexpressed by <italic>&#x003c0;</italic><sub><italic>T</italic></sub>=<italic>&#x003c8;</italic>+<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>+(1&#x02212;<italic>&#x003b8;</italic>)<italic>&#x003c0;</italic><sub><italic>P</italic></sub> with <italic>&#x003c0;</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>P</italic></sub> and <italic>&#x003c8;</italic> being nuisance parameters. These nuisance parameters can be eliminated by maximizing the null likelihood over the complete domain <italic>&#x003a9;</italic>. Similar to Tang and Tang [<xref ref-type="bibr" rid="CR18">18</xref>], the exact unconditional <italic>p</italic>-value for testing <italic>H</italic><sub>0</sub>:<italic>&#x003c8;</italic>&#x02264;0 via statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) based on <inline-formula id="IEq42"><inline-graphic xlink:href="12874_2014_1137_IEq42_HTML.gif"/></inline-formula> is defined as
<disp-formula id="Equk"><graphic xlink:href="12874_2014_1137_Equk_HTML.gif" position="anchor"/></disp-formula></p><p>where
<disp-formula id="Equl"><graphic xlink:href="12874_2014_1137_Equl_HTML.gif" position="anchor"/></disp-formula></p><p>and <inline-formula id="IEq43"><inline-graphic xlink:href="12874_2014_1137_IEq43_HTML.gif"/></inline-formula> is 1 if <inline-formula id="IEq44"><inline-graphic xlink:href="12874_2014_1137_IEq44_HTML.gif"/></inline-formula> and 0 otherwise.</p></sec><sec id="Sec9"><title>(4) Approximate unconditional method (AUM)</title><p>According to Tang and Tang [<xref ref-type="bibr" rid="CR18">18</xref>] and Tang, Tang and Rosner [<xref ref-type="bibr" rid="CR23">23</xref>], the exact unconditional test is always conservative, i.e., its corresponding type I error rate is always less than or equal to the prespecified significance level. Following Tang and Tang [<xref ref-type="bibr" rid="CR18">18</xref>], these nuisance parameters can be eliminated by evaluating their values at their corresponding RMLEs under <italic>&#x003c8;</italic>=0. The approximate unconditional <italic>p</italic>-value for testing <italic>H</italic><sub>0</sub>:<italic>&#x003c8;</italic>&#x02264;0 via statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) based on <inline-formula id="IEq45"><inline-graphic xlink:href="12874_2014_1137_IEq45_HTML.gif"/></inline-formula> can be defined as <inline-formula id="IEq46"><inline-graphic xlink:href="12874_2014_1137_IEq46_HTML.gif"/></inline-formula>.</p></sec><sec id="Sec10"><title>(5) Bootstrap-resampling method (BTM)</title><p>Hypothesis testing based on the bootstrap-resampling method is usually recommended when sample sizes (i.e., <italic>n</italic><sub><italic>T</italic></sub>, <italic>n</italic><sub><italic>R</italic></sub> and <italic>n</italic><sub><italic>P</italic></sub>) are small [<xref ref-type="bibr" rid="CR24">24</xref>] or data structure is sparse (e.g., <italic>x</italic><sub><italic>T</italic></sub> or <italic>x</italic><sub><italic>R</italic></sub> or <italic>x</italic><sub><italic>P</italic></sub> is close to zero or <italic>n</italic><sub><italic>T</italic></sub>, <italic>n</italic><sub><italic>R</italic></sub> and <italic>n</italic><sub><italic>P</italic></sub>, respectively). Given the observation <inline-formula id="IEq47"><inline-graphic xlink:href="12874_2014_1137_IEq47_HTML.gif"/></inline-formula>, we compute the RMLEs <inline-formula id="IEq48"><inline-graphic xlink:href="12874_2014_1137_IEq48_HTML.gif"/></inline-formula> and <inline-formula id="IEq49"><inline-graphic xlink:href="12874_2014_1137_IEq49_HTML.gif"/></inline-formula> of parameters <italic>&#x003c0;</italic><sub><italic>T</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003c0;</italic><sub><italic>P</italic></sub>, and calculate the observed value <inline-formula id="IEq50"><inline-graphic xlink:href="12874_2014_1137_IEq50_HTML.gif"/></inline-formula> of statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>). Based on the RMLEs <inline-formula id="IEq51"><inline-graphic xlink:href="12874_2014_1137_IEq51_HTML.gif"/></inline-formula> and <inline-formula id="IEq52"><inline-graphic xlink:href="12874_2014_1137_IEq52_HTML.gif"/></inline-formula>, we generate <italic>B</italic> bootstrap samples <inline-formula id="IEq53"><inline-graphic xlink:href="12874_2014_1137_IEq53_HTML.gif"/></inline-formula> from the following distribution: <inline-formula id="IEq54"><inline-graphic xlink:href="12874_2014_1137_IEq54_HTML.gif"/></inline-formula> for <italic>k</italic>=<italic>T</italic>,<italic>R</italic> and <italic>P</italic>. For each of the <italic>B</italic> bootstrap samples, we compute the observed value <inline-formula id="IEq55"><inline-graphic xlink:href="12874_2014_1137_IEq55_HTML.gif"/></inline-formula> of statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>). Hence, an approximate <italic>p</italic>-value for testing <italic>H</italic><sub>0</sub>:<italic>&#x003c8;</italic>&#x02264;0 via statistic <italic>T</italic><sub><italic>j</italic></sub> based on <inline-formula id="IEq56"><inline-graphic xlink:href="12874_2014_1137_IEq56_HTML.gif"/></inline-formula> is given by <inline-formula id="IEq57"><inline-graphic xlink:href="12874_2014_1137_IEq57_HTML.gif"/></inline-formula>.</p><p>For any given observation <inline-formula id="IEq58"><inline-graphic xlink:href="12874_2014_1137_IEq58_HTML.gif"/></inline-formula>, test statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) and <italic>p</italic>-value calculation method, we reject the null hypothesis <italic>H</italic><sub>0</sub> at the significance level <italic>&#x003b1;</italic> if <inline-formula id="IEq59"><inline-graphic xlink:href="12874_2014_1137_IEq59_HTML.gif"/></inline-formula> for <italic>k</italic>=AM, SA, EU, AU and BT.</p></sec></sec><sec id="Sec11"><title>Simulation study</title><p>Simulation studies are conducted to investigate the performance of various test statistics together with the five <italic>p</italic>-value calculation methods in small-sample designs (e.g., <italic>n</italic>=30 and 60, where <italic>n</italic>=<italic>n</italic><sub><italic>P</italic></sub>+<italic>n</italic><sub><italic>R</italic></sub>+<italic>n</italic><sub><italic>T</italic></sub> with the allocation ratios <italic>&#x003bb;</italic><sub><italic>P</italic></sub>: <italic>&#x003bb;</italic><sub><italic>R</italic></sub>: <italic>&#x003bb;</italic><sub><italic>T</italic></sub>=1: <italic>n</italic><sub><italic>R</italic></sub>/<italic>n</italic><sub><italic>P</italic></sub>: <italic>n</italic><sub><italic>T</italic></sub>/<italic>n</italic><sub><italic>P</italic></sub> taking to be 1:1:1, 1:2:2 and 1:2:3) in terms of type I error rate and power. For each (<italic>n</italic><sub><italic>P</italic></sub>,<italic>n</italic><sub><italic>R</italic></sub>,<italic>n</italic><sub><italic>T</italic></sub>), we consider the following probability settings [<xref ref-type="bibr" rid="CR19">19</xref>]: <italic>&#x003c0;</italic><sub><italic>P</italic></sub>=0.05,0.10,0.15,&#x02026;,0.50, <italic>&#x003c0;</italic><sub><italic>R</italic></sub>=<italic>&#x003c0;</italic><sub><italic>P</italic></sub>+0.05,<italic>&#x003c0;</italic><sub><italic>P</italic></sub>+0.10,&#x02026;,0.95, and <italic>&#x003c0;</italic><sub><italic>T</italic></sub>=<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>+(1&#x02212;<italic>&#x003b8;</italic>)<italic>&#x003c0;</italic><sub><italic>P</italic></sub>, which corresponds to a total of 11,340 configurations of (<italic>&#x003c0;</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>T</italic></sub>), and the following two non-inferiority margins: <italic>&#x003b8;</italic>=0.6 and 0.8. The nominal level is taken to be <italic>&#x003b1;</italic>=0.05. For the given values of <italic>n</italic> and allocation ratio <italic>&#x003bb;</italic><sub><italic>P</italic></sub>: <italic>&#x003bb;</italic><sub><italic>R</italic></sub>: <italic>&#x003bb;</italic><sub><italic>T</italic></sub>, <italic>n</italic><sub><italic>k</italic></sub> is given by <italic>n</italic><sub><italic>&#x02113;</italic></sub>=<italic>n</italic><italic>&#x003bb;</italic><sub><italic>k</italic></sub>/(<italic>&#x003bb;</italic><sub><italic>P</italic></sub>+<italic>&#x003bb;</italic><sub><italic>R</italic></sub>+<italic>&#x003bb;</italic><sub><italic>T</italic></sub>) for <italic>&#x02113;</italic>=<italic>P</italic>,<italic>R</italic> and <italic>T</italic>. Thus, given <italic>n</italic>, allocation ratio and (<italic>&#x003c0;</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>T</italic></sub>), the type I error rate for testing hypothesis <italic>H</italic><sub>0</sub>:<italic>&#x003c8;</italic>&#x02264;0 versus <italic>H</italic><sub>1</sub>:<italic>&#x003c8;</italic>&#x0003e;0 via test statistic <italic>T</italic><sub><italic>j</italic></sub> (<italic>j</italic>=<italic>W</italic>,<italic>R</italic>,<italic>L</italic>) at the significance level <italic>&#x003b1;</italic> is calculated by
<disp-formula id="Equm"><graphic xlink:href="12874_2014_1137_Equm_HTML.gif" position="anchor"/></disp-formula></p><p>for <italic>k</italic>=<italic>A</italic><italic>M</italic>,<italic>S</italic><italic>A</italic><italic>M</italic>,<italic>E</italic><italic>U</italic><italic>M</italic>,<italic>A</italic><italic>U</italic><italic>M</italic> and <italic>BTM</italic>, whilst the corresponding power can be evaluated by replacing <italic>H</italic><sub>0</sub> in <inline-formula id="IEq60"><inline-graphic xlink:href="12874_2014_1137_IEq60_HTML.gif"/></inline-formula> by <italic>H</italic><sub>1</sub>.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Simulation study</title><p>To compare the performance of AM, SAM, EUM, AUM and BTM together with test statistics <italic>T</italic><sub><italic>W</italic></sub>, <italic>T</italic><sub><italic>R</italic></sub> and <italic>T</italic><sub><italic>L</italic></sub> under the balanced and unbalanced designs, Figure <xref rid="Fig1" ref-type="fig">1</xref> presents boxplots of their corresponding type I error rates for <italic>n</italic>=30 and 60, and <italic>&#x003bb;</italic><sub><italic>P</italic></sub>: <italic>&#x003bb;</italic><sub><italic>R</italic></sub>: <italic>&#x003bb;</italic><sub><italic>T</italic></sub>=1:1:1, 1:2:2 and 1:2:3, where AMk, SAk, EUk, AUk and BTk represent AM, SAM, EUM, AUM and BTM for test statistic <italic>T</italic><sub>k</sub> with k=W, R and L, respectively. Here, each boxplot in Figure <xref rid="Fig1" ref-type="fig">1</xref> contains 2 (i.e., the number of non-inferiority margins) &#x000d7;11,340 (i.e., the number of configurations for (<italic>&#x003c0;</italic><sub><italic>P</italic></sub>,<italic>&#x003c0;</italic><sub><italic>R</italic></sub>,<italic>&#x003c0;</italic><sub><italic>T</italic></sub>))=22,680 data points. From Figure <xref rid="Fig1" ref-type="fig">1</xref>, we have the following findings. First, the medians of the type I error rates based on AUM and BTM are closer to the prespecified nominal level <italic>&#x003b1;</italic>=0.05 than those based on the other three <italic>p</italic>-value calculation methods for all three test statistics under consideration. Second, for AUM and BTM, the medians of the type I error rates for test statistics <italic>T</italic><sub><italic>W</italic></sub> and <italic>T</italic><sub><italic>R</italic></sub>, which are 0.0495 and 0.0501 for AUM and 0.0494 and 0.0494 for BTM respectively, are closer to <italic>&#x003b1;</italic>=0.05 than those for test statistic <italic>T</italic><sub><italic>L</italic></sub>, which are 0.0442 for AUM and 0.0442 for BTM. Third, for AM, SAM and EUM, their corresponding medians of type I error rates are 0.0649, 0.0455 and 0.0260 for test statistic <italic>T</italic><sub><italic>W</italic></sub>, 0.0504, 0.0455 and 0.0488 for test statistic <italic>T</italic><sub><italic>R</italic></sub>, and 0.0663, 0.1285 and 0.0332 for test statistic <italic>T</italic><sub><italic>L</italic></sub>, respectively, which indicate that (i) the AM is liberal for test statistics <italic>T</italic><sub><italic>W</italic></sub> and <italic>T</italic><sub><italic>L</italic></sub>, whilst it is valid for test statistic <italic>T</italic><sub><italic>R</italic></sub>; (ii) the SAM can improve the accuracy of the normal approximation for test statistics <italic>T</italic><sub><italic>W</italic></sub> and <italic>T</italic><sub><italic>R</italic></sub>; and (iii) the EUM is conservative for all test statistics. Fourth, the proportions of configurations whose type I error rates lie in the interval (0.045,0.055) for AM, SAM, EUM, AUM and BTM are 0.0747, 0.4691, 0.0710, 0.5154 and 0.7994 for <italic>T</italic><sub><italic>W</italic></sub>, 0.5605, 0.4605, 0.4753, 0.7167 and 0.8370 for <italic>T</italic><sub><italic>R</italic></sub>, and 0.0784, 0.0800, 0.0691, 0.4056 and 0.4889 for <italic>T</italic><sub><italic>L</italic></sub>, respectively, which show that (i) AUM and BTM outperform the other three <italic>p</italic>-value calculation procedures, and (ii) <italic>T</italic><sub><italic>R</italic></sub> behaves better than the other two test statistics regardless of <italic>p</italic>-value calculation procedures. Fifth, the median of the type I error rates becomes more close to the prespecified nominal level as the total sample size <italic>n</italic> increases, whilst at the same time the variability of the type I error rates decreases. Sixth, the variability of the type I error rates for unbalanced designs is not significantly different from that for the balanced designs.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Boxplots of the type I error rates of various test procedures together with three statistics when testing the non-inferiority hypothesis (2</bold>
<bold><italic>.</italic></bold>
<bold>2) at</bold>
<bold><italic>&#x003b1;</italic></bold>
<bold>=0</bold>
<bold><italic>.</italic></bold>
<bold>05.</bold> AMk, SAk, EUk, AUk and BTk represent the AM, SA, EU, AU and BT test procedures with test statistic <italic>T</italic>
<sub><italic>k</italic></sub> for <italic>k</italic> = W, R and T, respectively.</p></caption><graphic xlink:href="12874_2014_1137_Fig1_HTML" id="d30e2652"/></fig></p><p>To investigate the sensitivity of various <italic>p</italic>-value calculation procedures (i.e., AM, SAM, EUM, AUM and BTM) to different test statistics, Figure <xref rid="Fig2" ref-type="fig">2</xref> presents boxplots of their corresponding type I error rates against <italic>&#x003c0;</italic><sub><italic>P</italic></sub> for test statistics <italic>T</italic><sub><italic>W</italic></sub>, <italic>T</italic><sub><italic>R</italic></sub> and <italic>T</italic><sub><italic>L</italic></sub>. Examination of Figure <xref rid="Fig2" ref-type="fig">2</xref> shows that there is no significant effect of <italic>&#x003c0;</italic><sub><italic>P</italic></sub> on the type I error rate.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Boxplots of the type I error rates of various test procedures together with three statistics against</bold>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>P</italic></bold></sub>
<bold>when testing the non-inferiority hypothesis (2</bold>
<bold><italic>.</italic></bold>
<bold>2) at</bold>
<bold><italic>&#x003b1;</italic></bold>
<bold>=0</bold>
<bold><italic>.</italic></bold>
<bold>05.</bold> EUk, AUk and BTk represent the EU, AU and BT test procedures with statistic <italic>T</italic>
<sub>k</sub> for k = W,R and T, respectively.</p></caption><graphic xlink:href="12874_2014_1137_Fig2_HTML" id="d30e2743"/></fig></p><p>We also calculate powers of the five <italic>p</italic>-value calculation procedures together with the three test statistics at the nominal level <italic>&#x003b1;</italic>=0.05 when <italic>&#x003c0;</italic><sub><italic>T</italic></sub>=<italic>&#x003c0;</italic><sub><italic>R</italic></sub> and <italic>&#x003b8;</italic>=0.6 with the following settings: <italic>n</italic>=30 and 60, <italic>&#x003c0;</italic><sub><italic>P</italic></sub>=0.15 and 0.3, and <italic>&#x003c0;</italic><sub><italic>R</italic></sub>=0.5,0.8 and 0.95 for the balanced allocation 1:1:1 and unbalanced allocation 1:2:3. Results are reported in Table <xref rid="Tab1" ref-type="table">1</xref>. Examination of Table <xref rid="Tab1" ref-type="table">1</xref> indicates that (i) <italic>T</italic><sub><italic>R</italic></sub> is generally more powerful than <italic>T</italic><sub><italic>W</italic></sub> and <italic>T</italic><sub><italic>L</italic></sub> for the EUM except for <italic>&#x003c0;</italic><sub><italic>R</italic></sub>=0.95 with the unbalanced designs, (ii) <italic>T</italic><sub><italic>W</italic></sub> and <italic>T</italic><sub><italic>R</italic></sub> have similar powers for AM, AUM and BTM under our considered settings, (iii) a slight power difference is observed between <italic>T</italic><sub><italic>R</italic></sub> and <italic>T</italic><sub><italic>L</italic></sub> for AUM and BTM, (iv) there is slight power difference between balanced and unbalanced designs, and (v) power increases as <italic>n</italic> increases regardless of <italic>p</italic>-value calculation procedures or test statistics. Hence, we would recommend both AUM and BTM with <italic>T</italic><sub><italic>R</italic></sub> for hypothesis testing.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Exact powers (</bold>
<bold><italic>%</italic></bold>
<bold>) of various test procedures together with three statistics when</bold>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>T</italic></bold></sub>
<bold>=</bold>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
<bold>with</bold>
<bold><italic>n</italic></bold>
<bold>=30 and 60,</bold>
<bold><italic>&#x003b8;</italic></bold>
<bold>=0</bold>
<bold><italic>.</italic></bold>
<bold>6and</bold>
<bold><italic>&#x003b1;</italic></bold>
<bold>=0</bold>
<bold><italic>.</italic></bold>
<bold>05</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left"/><th align="left"/><th colspan="3">AM</th><th colspan="3">SAM</th><th colspan="3">EUM</th><th colspan="3">AUM</th><th colspan="3">BTM</th></tr><tr><th>
<bold><italic>n</italic></bold>
</th><th>
<bold><italic>&#x003bb;</italic></bold>
<sub><bold><italic>P</italic></bold></sub>: <bold><italic>&#x003bb;</italic></bold>
<sub><bold><italic>R</italic></bold></sub>: <bold><italic>&#x003bb;</italic></bold>
<sub><bold><italic>T</italic></bold></sub>
</th><th>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>P</italic></bold></sub>
</th><th>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th></tr></thead><tbody><tr><td align="center">30</td><td align="center">1:1:1</td><td align="center">0.15</td><td align="center">0.5</td><td align="center">13.4</td><td align="center">12.3</td><td align="center">13.9</td><td align="center">43.6</td><td align="center">21.2</td><td align="center">22.5</td><td align="center">5.0</td><td align="center">18.1</td><td align="center">15.3</td><td align="center">18.2</td><td align="center">18.2</td><td align="center">14.9</td><td align="center">17.9</td><td align="center">18.0</td><td align="center">16.2</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">44.2</td><td align="center">43.9</td><td align="center">38.0</td><td align="center">42.6</td><td align="center">72.4</td><td align="center">30.0</td><td align="center">28.1</td><td align="center">43.5</td><td align="center">40.3</td><td align="center">42.1</td><td align="center">42.1</td><td align="center">39.7</td><td align="center">43.7</td><td align="center">43.9</td><td align="center">42.1</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">86.0</td><td align="center">85.8</td><td align="center">75.2</td><td align="center">95.6</td><td align="center">97.7</td><td align="center">36.8</td><td align="center">67.8</td><td align="center">79.1</td><td align="center">76.0</td><td align="center">74.2</td><td align="center">74.2</td><td align="center">71.3</td><td align="center">75.8</td><td align="center">75.4</td><td align="center">75.0</td></tr><tr><td align="center"/><td align="center"/><td align="center">0.3</td><td align="center">0.5</td><td align="center">8.8</td><td align="center">7.5</td><td align="center">8.3</td><td align="center">39.9</td><td align="center">23.2</td><td align="center">14.8</td><td align="center">2.9</td><td align="center">10.7</td><td align="center">8.5</td><td align="center">10.8</td><td align="center">10.8</td><td align="center">9.3</td><td align="center">11.1</td><td align="center">11.1</td><td align="center">9.1</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">30.1</td><td align="center">29.2</td><td align="center">22.0</td><td align="center">21.1</td><td align="center">35.6</td><td align="center">26.6</td><td align="center">15.9</td><td align="center">29.2</td><td align="center">24.8</td><td align="center">30.0</td><td align="center">30.0</td><td align="center">26.8</td><td align="center">30.2</td><td align="center">30.7</td><td align="center">29.0</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">66.3</td><td align="center">64.1</td><td align="center">45.6</td><td align="center">80.6</td><td align="center">88.3</td><td align="center">26.4</td><td align="center">42.5</td><td align="center">52.7</td><td align="center">49.8</td><td align="center">59.4</td><td align="center">59.4</td><td align="center">57.1</td><td align="center">60.0</td><td align="center">59.7</td><td align="center">59.4</td></tr><tr><td align="center"/><td align="center">1:2:3</td><td align="center">0.15</td><td align="center">0.5</td><td align="center">14.2</td><td align="center">11.9</td><td align="center">18.6</td><td align="center">33.2</td><td align="center">28.2</td><td align="center">24.7</td><td align="center">13.2</td><td align="center">17.9</td><td align="center">13.7</td><td align="center">21.7</td><td align="center">21.7</td><td align="center">19.7</td><td align="center">20.3</td><td align="center">20.0</td><td align="center">18.4</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">43.6</td><td align="center">41.4</td><td align="center">48.3</td><td align="center">58.9</td><td align="center">81.3</td><td align="center">29.0</td><td align="center">43.4</td><td align="center">45.4</td><td align="center">36.3</td><td align="center">53.1</td><td align="center">52.3</td><td align="center">44.8</td><td align="center">51.5</td><td align="center">51.1</td><td align="center">44.4</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">83.0</td><td align="center">82.9</td><td align="center">83.9</td><td align="center">97.1</td><td align="center">98.8</td><td align="center">36.0</td><td align="center">85.6</td><td align="center">79.6</td><td align="center">82.6</td><td align="center">85.9</td><td align="center">84.3</td><td align="center">79.9</td><td align="center">85.4</td><td align="center">84.9</td><td align="center">80.6</td></tr><tr><td align="center"/><td align="center"/><td align="center">0.3</td><td align="center">0.5</td><td align="center">8.6</td><td align="center">7.2</td><td align="center">10.3</td><td align="center">36.2</td><td align="center">25.0</td><td align="center">18.7</td><td align="center">7.9</td><td align="center">10.8</td><td align="center">7.6</td><td align="center">12.4</td><td align="center">12.2</td><td align="center">10.5</td><td align="center">11.9</td><td align="center">11.7</td><td align="center">9.8</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">29.7</td><td align="center">27.4</td><td align="center">30.1</td><td align="center">26.1</td><td align="center">57.9</td><td align="center">25.9</td><td align="center">28.9</td><td align="center">31.9</td><td align="center">22.7</td><td align="center">35.0</td><td align="center">33.6</td><td align="center">28.2</td><td align="center">34.4</td><td align="center">33.7</td><td align="center">29.5</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">62.4</td><td align="center">61.8</td><td align="center">62.8</td><td align="center">85.5</td><td align="center">95.3</td><td align="center">36.9</td><td align="center">66.4</td><td align="center">63.0</td><td align="center">60.9</td><td align="center">65.8</td><td align="center">64.5</td><td align="center">62.3</td><td align="center">66.3</td><td align="center">65.9</td><td align="center">64.0</td></tr><tr><td align="center">60</td><td align="center">1:1:1</td><td align="center">0.15</td><td align="center">0.5</td><td align="center">19.0</td><td align="center">19.0</td><td align="center">18.4</td><td align="center">33.7</td><td align="center">47.5</td><td align="center">24.3</td><td align="center">10.7</td><td align="center">11.3</td><td align="center">14.2</td><td align="center">29.3</td><td align="center">29.4</td><td align="center">28.3</td><td align="center">28.0</td><td align="center">28.1</td><td align="center">27.2</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">65.8</td><td align="center">67.8</td><td align="center">59.6</td><td align="center">85.2</td><td align="center">92.4</td><td align="center">38.9</td><td align="center">55.0</td><td align="center">56.3</td><td align="center">48.7</td><td align="center">71.4</td><td align="center">71.4</td><td align="center">71.4</td><td align="center">71.1</td><td align="center">71.1</td><td align="center">70.7</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">97.9</td><td align="center">98.6</td><td align="center">96.6</td><td align="center">96.6</td><td align="center">96.7</td><td align="center">50.3</td><td align="center">95.9</td><td align="center">96.7</td><td align="center">89.3</td><td align="center">97.7</td><td align="center">97.7</td><td align="center">97.7</td><td align="center">97.7</td><td align="center">97.7</td><td align="center">97.7</td></tr><tr><td align="center"/><td align="center"/><td align="center">0.3</td><td align="center">0.5</td><td align="center">9.7</td><td align="center">9.4</td><td align="center">9.5</td><td align="center">43.2</td><td align="center">21.5</td><td align="center">16.9</td><td align="center">4.7</td><td align="center">5.3</td><td align="center">4.2</td><td align="center">17.0</td><td align="center">17.2</td><td align="center">15.3</td><td align="center">14.1</td><td align="center">14.3</td><td align="center">13.1</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">46.5</td><td align="center">47.1</td><td align="center">39.8</td><td align="center">54.6</td><td align="center">79.8</td><td align="center">33.2</td><td align="center">35.4</td><td align="center">36.9</td><td align="center">37.1</td><td align="center">50.9</td><td align="center">50.9</td><td align="center">50.8</td><td align="center">49.7</td><td align="center">50.3</td><td align="center">50.0</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">91.3</td><td align="center">93.3</td><td align="center">85.7</td><td align="center">95.3</td><td align="center">96.0</td><td align="center">47.0</td><td align="center">85.9</td><td align="center">87.8</td><td align="center">71.3</td><td align="center">88.0</td><td align="center">88.0</td><td align="center">88.0</td><td align="center">89.6</td><td align="center">89.3</td><td align="center">89.5</td></tr><tr><td align="center"/><td align="center">1:2:3</td><td align="center">0.15</td><td align="center">0.5</td><td align="center">20.5</td><td align="center">20.2</td><td align="center">22.2</td><td align="center">29.6</td><td align="center">53.8</td><td align="center">27.9</td><td align="center">24.1</td><td align="center">22.1</td><td align="center">24.2</td><td align="center">31.0</td><td align="center">30.8</td><td align="center">28.3</td><td align="center">31.7</td><td align="center">31.1</td><td align="center">28.2</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">72.5</td><td align="center">72.5</td><td align="center">69.1</td><td align="center">92.3</td><td align="center">96.4</td><td align="center">40.9</td><td align="center">73.9</td><td align="center">73.3</td><td align="center">79.2</td><td align="center">77.0</td><td align="center">76.9</td><td align="center">75.9</td><td align="center">78.3</td><td align="center">78.1</td><td align="center">76.7</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">98.6</td><td align="center">98.6</td><td align="center">98.0</td><td align="center">99.9</td><td align="center">99.9</td><td align="center">50.6</td><td align="center">98.6</td><td align="center">98.9</td><td align="center">92.4</td><td align="center">99.1</td><td align="center">99.0</td><td align="center">99.0</td><td align="center">98.5</td><td align="center">98.5</td><td align="center">98.4</td></tr><tr><td align="center"/><td align="center"/><td align="center">0.3</td><td align="center">0.5</td><td align="center">10.3</td><td align="center">10.0</td><td align="center">10.3</td><td align="center">42.9</td><td align="center">25.0</td><td align="center">20.1</td><td align="center">12.3</td><td align="center">10.3</td><td align="center">10.1</td><td align="center">15.8</td><td align="center">15.7</td><td align="center">13.5</td><td align="center">15.8</td><td align="center">15.4</td><td align="center">13.4</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.8</td><td align="center">49.3</td><td align="center">49.2</td><td align="center">45.1</td><td align="center">64.6</td><td align="center">84.1</td><td align="center">36.2</td><td align="center">52.0</td><td align="center">48.4</td><td align="center">38.0</td><td align="center">52.0</td><td align="center">52.0</td><td align="center">51.0</td><td align="center">55.5</td><td align="center">55.4</td><td align="center">54.1</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center">0.95</td><td align="center">90.4</td><td align="center">90.3</td><td align="center">88.7</td><td align="center">99.1</td><td align="center">99.4</td><td align="center">51.3</td><td align="center">90.9</td><td align="center">92.5</td><td align="center">82.4</td><td align="center">92.1</td><td align="center">92.0</td><td align="center">92.0</td><td align="center">91.8</td><td align="center">91.7</td><td align="center">91.7</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Real data example</title><p>An example from a pharmacological study of patients with functional dyspepsia (FD) and a placebo-controlled trail of subjects with acute migraine is used to illustrate our proposed methodologies. This example has been analyzed by Holtmann et al. [<xref ref-type="bibr" rid="CR25">25</xref>] and Tang and Tang [<xref ref-type="bibr" rid="CR14">14</xref>]. In this example, cisapride and simethicone can be regarded as the existing reference and new experimental treatments, respectively. In that study, among <italic>n</italic>=178 patients of FD, <italic>n</italic><sub><italic>P</italic></sub>=61, <italic>n</italic><sub><italic>R</italic></sub>=59 and <italic>n</italic><sub><italic>T</italic></sub>=58 were randomized and treated in a doubly dummy technique with placebo, cisapride and simethicone, respectively; adverse events (e.g., diarrhea and pain) were happened in <italic>x</italic><sub><italic>P</italic></sub>=7, <italic>x</italic><sub><italic>R</italic></sub>=10 and <italic>x</italic><sub><italic>T</italic></sub>=12 patients treated with placebo, cisapride and simethicone, respectively. It is of interest to test if simethicone is not inferior to cisapride in terms of rate of reporting adverse event in the presence of placebo. Given <italic>&#x003b8;</italic>=0.6 and 0.8, the corresponding <italic>p</italic>-values for testing <italic>H</italic><sub>0</sub>:(<italic>&#x003c0;</italic><sub><italic>T</italic></sub>&#x02212;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>)/(<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02212;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>)&#x02264;<italic>&#x003b8;</italic> versus <italic>H</italic><sub>1</sub>:(<italic>&#x003c0;</italic><sub><italic>T</italic></sub>&#x02212;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>)/(<italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02212;<italic>&#x003c0;</italic><sub><italic>P</italic></sub>)&#x0003e;<italic>&#x003b8;</italic> based on the five <italic>p</italic>-value calculation procedures and three test statistics are reported in Table <xref rid="Tab2" ref-type="table">2</xref>. By Table <xref rid="Tab2" ref-type="table">2</xref>, there is no evidence to show that simethicone is noninferior to cisapride in the presence of placebo at the nominal level <italic>&#x003b1;</italic>=0.05, which is consistent with that given in Tang and Tang [<xref ref-type="bibr" rid="CR14">14</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Various</bold>
<bold><italic>p</italic></bold>
<bold>-values for the pharmacological data set at the nominal level</bold>
<bold><italic>&#x003b1;</italic></bold>
<bold>=5</bold>
<bold><italic>%</italic></bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th colspan="3">
<bold><italic>&#x003b8;</italic></bold>=0<bold><italic>.</italic></bold>6</th><th align="left"/><th colspan="3">
<bold><italic>&#x003b8;</italic></bold>=0<bold><italic>.</italic></bold>8</th></tr><tr><th>Test method</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th><th align="left"/><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>W</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
</th><th>
<bold><italic>T</italic></bold>
<sub><bold><italic>L</italic></bold></sub>
</th></tr></thead><tbody><tr><td align="center">AM</td><td align="center">0.173</td><td align="center">0.162</td><td align="center">0.164</td><td align="center"/><td align="center">0.234</td><td align="center">0.229</td><td align="center">0.230</td></tr><tr><td align="center">SAM</td><td align="center">0.494</td><td align="center">0.494</td><td align="center">0.140</td><td align="center"/><td align="center">0.497</td><td align="center">0.497</td><td align="center">0.162</td></tr><tr><td align="center">EUM</td><td align="center">0.185</td><td align="center">0.181</td><td align="center">0.192</td><td align="center"/><td align="center">0.233</td><td align="center">0.202</td><td align="center">0.210</td></tr><tr><td align="center">AUM</td><td align="center">0.166</td><td align="center">0.165</td><td align="center">0.186</td><td align="center"/><td align="center">0.232</td><td align="center">0.230</td><td align="center">0.249</td></tr><tr><td align="center">BTM</td><td align="center">0.504</td><td align="center">0.502</td><td align="center">0.519</td><td align="center"/><td align="center">0.516</td><td align="center">0.514</td><td align="center">0.530</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>Simulation results demonstrate that our proposed score test statistic outperforms other test statistics in terms of type I error rate and power under our considered settings. The approximate unconditional and bootstrap-resampling methods perform better than other <italic>p</italic>-value calculation procedures in the sense that their corresponding type I error rates are closer to the prespecified nominal level and their corresponding powers are larger than those of other <italic>p</italic>-value calculation procedures. The exact unconditional method is conservative and time-consuming when sample sizes are large (e.g., see the 6th column in Table <xref rid="Tab3" ref-type="table">3</xref>). The asymptotic tests are liberal since their type I error rates are greater than the prespecified nominal level <italic>&#x003b1;</italic>=0.05 in most cases. Comparing the approximate and exact unconditional methods, the approximate unconditional method provides a good alternative to the exact unconditional method in terms of computing time (e.g., see the 6th and 7th columns in Table <xref rid="Tab3" ref-type="table">3</xref>) and type I error rate when sample sizes are large. In contrast, the computing burden of the bootstrap-resampling method is heavier than that of the approximate unconditional method (e.g., see the last two columns in Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Computing time (minutes) of the Type I error rates for 11340 configurations of (</bold>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>P</italic></bold></sub>
<bold>,</bold>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>R</italic></bold></sub>
<bold>,</bold>
<bold><italic>&#x003c0;</italic></bold>
<sub><bold><italic>T</italic></bold></sub>
<bold>) together with three test statistics under five test methods</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<bold><italic>&#x003bb;</italic></bold>
<sub><bold><italic>P</italic></bold></sub>:<bold><italic>&#x003bb;</italic></bold>
<sub><bold><italic>R</italic></bold></sub>:<bold><italic>&#x003bb;</italic></bold>
<sub><bold><italic>T</italic></bold></sub>
</th><th>
<bold><italic>&#x003b8;</italic></bold>
</th><th>n</th><th>AM</th><th>SAM</th><th>EUM</th><th>AUM</th><th>BTM</th></tr></thead><tbody><tr><td align="center">1:2:3</td><td align="center">0.6</td><td align="center">30</td><td align="center">3.3</td><td align="center">269</td><td align="center">2920</td><td align="center">55.75</td><td align="center">11700</td></tr><tr><td align="center"/><td align="center"/><td align="center">60</td><td align="center">3.8</td><td align="center">356</td><td align="center">130950</td><td align="center">357.3</td><td align="center">20700</td></tr></tbody></table></table-wrap></p><p>In this article, we concentrate on a three-arm non-inferiority trial with binary endpoints in which the marginal is defined as a fraction of the unknown difference in response probabilities between reference and placebo. The corresponding hypothesis (i.e., <inline-formula id="IEq61"><inline-graphic xlink:href="12874_2014_1137_IEq61_HTML.gif"/></inline-formula> or <italic>H</italic><sub>0</sub>:<italic>&#x003c0;</italic><sub><italic>T</italic></sub>&#x02212;<italic>&#x003b8;</italic><italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02212;(1&#x02212;<italic>&#x003b8;</italic>)<italic>&#x003c0;</italic><sub><italic>P</italic></sub>&#x02264;0) is considered since it is simple and only one single hypothesis is involved (e.g., see [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]). However, three-arm non-inferiority hypotheses with the marginal defined as the prespecified difference between treatments have received a considerable attention in recent years (e.g., see [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]). They can be generally classified as the union type hypotheses (i.e., <italic>H</italic><sub><italic>U</italic>0</sub>: <italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02265;<italic>h</italic><sub><italic>P</italic></sub>(<italic>&#x003c0;</italic><sub><italic>P</italic></sub>) or <italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02265;<italic>h</italic><sub><italic>T</italic></sub>(<italic>&#x003c0;</italic><sub><italic>T</italic></sub>)) or the intersection type hypotheses (i.e., <italic>H</italic><sub><italic>U</italic>0</sub>: <italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02265;<italic>h</italic><sub><italic>P</italic></sub>(<italic>&#x003c0;</italic><sub><italic>P</italic></sub>) and <italic>&#x003c0;</italic><sub><italic>R</italic></sub>&#x02265;<italic>h</italic><sub><italic>T</italic></sub>(<italic>&#x003c0;</italic><sub><italic>T</italic></sub>)), where <italic>h</italic><sub><italic>P</italic></sub>(.) and <italic>h</italic><sub><italic>T</italic></sub>(.) are any functions [<xref ref-type="bibr" rid="CR15">15</xref>]. For specific choices of <italic>h</italic><sub><italic>P</italic></sub>(.) and <italic>h</italic><sub><italic>R</italic></sub>(.), this includes, for examples, hypotheses on the differences, the relative risks or the odds ratio of the proportions. While the union type hypotheses are suitable for showing both the superiority of the standard treatment as compared to placebo and the inferiority of the test treatment as compared to the standard treatment, the intersection type hypotheses are suitable for showing the test treatment is as effective as the standard or placebo treatments. We are working on statistical inference on a three-arm non-inferiority trial with the margin being a prespecifided difference between treatments when the primary endpoints are binary.</p></sec><sec id="Sec16" sec-type="conclusions"><title>Conclusions</title><p>According to the aforementioned observations, we can draw the following conclusions. In terms of type I error rates and powers, the approximate unconditional and bootstrap-resampling methods with score test statistic are recommended for hypothesis testing purpose when sample sizes are small in a three-arm non-inferiority trial. In terms of time-consuming and type I error rates and powers, the approximate unconditional method with score test statistic behaves the best among our considered <italic>p</italic>-value calculation procedures and test statistics.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>NST conceived of research questions, developed methods and revised the manuscript; BY carried out statistical analysis and drafted the manuscript; MLT interpreted results and revised the manuscript. All authors commented on successive drafts, and read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by the grants from the National Science Foundation of China (11225103), and Research Fund for the Doctoral Program of Higher Education of China (20115301110004). The work of the third author was partially supported by the General Research Fund from the Research Grants Council of the Hong Kong Special Administrative Region, China (UGC/FDS14/P01/14).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunnett</surname><given-names>CW</given-names></name><name><surname>Gent</surname><given-names>M</given-names></name></person-group><article-title><bold>Significance testing to establish equivalence between treatments with special reference to data in the form of 2 &#x000d7; 2 tables</bold></article-title><source>Biometrics</source><year>1977</year><volume>33</volume><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.2307/2529457</pub-id><pub-id pub-id-type="pmid">588654</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tango</surname><given-names>T</given-names></name></person-group><article-title><bold>Equivalence test and confidence interval for the difference in proportions for the paired-sample design</bold></article-title><source>Stat Med</source><year>1998</year><volume>17</volume><fpage>891</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19980430)17:8&#x0003c;891::AID-SIM780&#x0003e;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">9595618</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>NS</given-names></name><name><surname>Tang</surname><given-names>ML</given-names></name><name><surname>Chan</surname><given-names>ISF</given-names></name></person-group><article-title><bold>On tests of equivalence via non-unity relative risk for matched-pair design</bold></article-title><source>Stat Med</source><year>2003</year><volume>22</volume><fpage>1217</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1002/sim.1213</pub-id><pub-id pub-id-type="pmid">12687652</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name></person-group><article-title><bold>A group sequential type design for three-arm non-inferiority trials with binary endpoints</bold></article-title><source>Biom J</source><year>2010</year><volume>52</volume><fpage>504</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1002/bimj.200900188</pub-id><pub-id pub-id-type="pmid">20645389</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hida</surname><given-names>E</given-names></name><name><surname>Tango</surname><given-names>T</given-names></name></person-group><article-title><bold>Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints</bold></article-title><source>J Biopharm Stat</source><year>2013</year><volume>23</volume><fpage>774</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1080/10543406.2013.789893</pub-id><pub-id pub-id-type="pmid">23799810</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>GG</given-names></name><name><surname>R&#x000f6;hmel</surname><given-names>J</given-names></name></person-group><article-title><bold>Hypothesis testing in the gold standard design for proving the efficacy of an experimental treatment relative to placebo and a reference</bold></article-title><source>J Biopharm Stat</source><year>2004</year><volume>14</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1081/BIP-120037182</pub-id><pub-id pub-id-type="pmid">15206529</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hida</surname><given-names>E</given-names></name><name><surname>Tango</surname><given-names>T</given-names></name></person-group><article-title><bold>On the three-arm non-inferiority trial including a placebo with a prespecified margin</bold></article-title><source>Stat Med</source><year>2011</year><volume>30</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1002/sim.4099</pub-id><pub-id pub-id-type="pmid">21213340</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>GG</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name></person-group><article-title><bold>Nonparametric analysis of covariance and its role in non-inferiority clinical trials</bold></article-title><source>Drug Inf J</source><year>1999</year><volume>33</volume><fpage>1145</fpage><lpage>1159</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pigeot</surname><given-names>I</given-names></name><name><surname>Schafer</surname><given-names>J</given-names></name><name><surname>Rohmel</surname><given-names>J</given-names></name><name><surname>Hauschke</surname><given-names>D</given-names></name></person-group><article-title><bold>Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo</bold></article-title><source>Stat Med</source><year>2003</year><volume>22</volume><fpage>883</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1002/sim.1450</pub-id><pub-id pub-id-type="pmid">12627407</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koti</surname><given-names>KM</given-names></name></person-group><article-title><bold>Use of the fieller-hinkley distribution of the ratio of random variables in testing for noninferiority</bold></article-title><source>J Biopharm Stat</source><year>2007</year><volume>17</volume><fpage>215</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1080/10543400601177335</pub-id><pub-id pub-id-type="pmid">17365219</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>M</given-names></name><name><surname>Vonk</surname><given-names>R</given-names></name><name><surname>Hothorn</surname><given-names>LA</given-names></name></person-group><article-title><bold>Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity</bold></article-title><source>Stat Med</source><year>2008</year><volume>27</volume><fpage>490</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/sim.3052</pub-id><pub-id pub-id-type="pmid">17853384</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Nathoo</surname><given-names>F</given-names></name><name><surname>G&#x000f6;nen</surname><given-names>M</given-names></name><name><surname>Tiwari</surname><given-names>RC</given-names></name></person-group><article-title><bold>Assessing noninferiority in a three-arm trial using the bayesian approach</bold></article-title><source>Stat Med</source><year>2011</year><volume>30</volume><fpage>1795</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1002/sim.4244</pub-id><pub-id pub-id-type="pmid">21520456</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamalo</surname><given-names>MA</given-names></name><name><surname>Muthukumarana</surname><given-names>S</given-names></name><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Tiwari</surname><given-names>RC</given-names></name></person-group><article-title><bold>A generalized p-value approach for assessing noninferiority in a three-arm trial</bold></article-title><source>Stat Methods Med Res</source><year>2013</year><volume>22</volume><fpage>261</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1177/0962280210395739</pub-id><pub-id pub-id-type="pmid">21300626</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>ML</given-names></name><name><surname>Tang</surname><given-names>NS</given-names></name></person-group><article-title><bold>Tests of non-inferiority via rate difference for three-arm clinical trials with placebo</bold></article-title><source>J Biopharm Stat</source><year>2004</year><volume>14</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1081/BIP-120037184</pub-id><pub-id pub-id-type="pmid">15206531</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munk</surname><given-names>A</given-names></name><name><surname>Mielke</surname><given-names>M</given-names></name><name><surname>Skipka</surname><given-names>G</given-names></name><name><surname>Freitag</surname><given-names>G</given-names></name></person-group><article-title><bold>Testing noninferiority in three-armed clinical trials based on likelihood ratio statistics</bold></article-title><source>Canadiaan J Stat</source><year>2007</year><volume>35</volume><fpage>413</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1002/cjs.5550350306</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JT</given-names></name><name><surname>Tzeng</surname><given-names>CS</given-names></name><name><surname>Tsou</surname><given-names>HH</given-names></name></person-group><article-title><bold>Establishing non-inferiority of a new treatment in a three-arm trial: apply a step-down hierarchical model in a papulopustular acne study and an oral prophylactic antibiotics study</bold></article-title><source>Intl J Stat Med Res</source><year>2014</year><volume>3</volume><fpage>11</fpage><lpage>20</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>J</given-names></name></person-group><source>Saddlepoint Approximations</source><year>1995</year><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford Science Publications</publisher-name></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>NS</given-names></name><name><surname>Tang</surname><given-names>ML</given-names></name></person-group><article-title><bold>Exact unconditional inference for risk ratio in a correlated 2 &#x000d7; 2 table with structural zero</bold></article-title><source>Biometrics</source><year>2002</year><volume>58</volume><fpage>972</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1111/j.0006-341X.2002.00972.x</pub-id><pub-id pub-id-type="pmid">12495152</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieser</surname><given-names>M</given-names></name><name><surname>Friede</surname><given-names>T</given-names></name></person-group><article-title><bold>Planning and analysis of three-arm non-inferiority trials with binary endpoints</bold></article-title><source>Stat Med</source><year>2007</year><volume>26</volume><fpage>253</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1002/sim.2543</pub-id><pub-id pub-id-type="pmid">16685703</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwelder</surname><given-names>WC</given-names></name></person-group><article-title><bold>Proving the null hypothesis in clinical trials</bold></article-title><source>Control Clin Trials</source><year>1982</year><volume>3</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(82)90024-1</pub-id><pub-id pub-id-type="pmid">7160191</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrington</surname><given-names>CP</given-names></name><name><surname>Manning</surname><given-names>G</given-names></name></person-group><article-title><bold>Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk</bold></article-title><source>Stat Med</source><year>1990</year><volume>9</volume><fpage>1447</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1002/sim.4780091208</pub-id><pub-id pub-id-type="pmid">2281232</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>BY</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name></person-group><article-title><bold>Saddlepoint approximations for marginal and conditional probabilities of transformed variables</bold></article-title><source>Ann Stat</source><year>1994</year><volume>22</volume><fpage>1115</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1214/aos/1176325620</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>ML</given-names></name><name><surname>Tang</surname><given-names>NS</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name></person-group><article-title><bold>Statistical inference for correlated data in ophthalmologic studies</bold></article-title><source>Stat Med</source><year>2006</year><volume>25</volume><fpage>2271</fpage><lpage>2783</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Efron</surname><given-names>B</given-names></name><name><surname>Tibshirani</surname><given-names>RJ</given-names></name></person-group><source>An Introduction to the Bootstrap</source><year>1993</year><publisher-loc>Boca Raton</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtmann</surname><given-names>G</given-names></name><name><surname>Gschossmann</surname><given-names>J</given-names></name><name><surname>Mayr</surname><given-names>P</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title><bold>A randomized placebo-controlled trail of simethicone and cisapride for the treatment of patients with functional dyspepsia</bold></article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>1641</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2002.01322.x</pub-id><pub-id pub-id-type="pmid">12197843</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR26"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2288/14/134/prepub">http://www.biomedcentral.com/1471-2288/14/134/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>